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Network meta-analysis of ordered outcomes: comparison 
of a multinomial logistic and proportional odds model
Chrissy van Beurden-Tan, Walter Bouwmeester, Craig Bennison, 





Background: Network meta-analysis (NMA) techniques have been developed to study 
relative treatment effects for several outcome types from similar patient populations that 
have not been compared directly in a randomized clinical trial. No literature exists comparing 
modelling methods of NMA for ordered categorical data, though several modelling methods 
are available with different characteristics. This study compared the proportional odds (PO) 
modelling method with the multinomial logistic (ML) modelling method for NMA in ordered 
categorical datasets, based on model fit and other qualitative characteristics. 
Methods: The models were evaluated in a clinical dataset including ordered response 
categories of psoriasis patients to four different treatments. In addition, to contrast model 
performance, two extreme oncology datasets were simulated, one which exactly satisfied the 
PO assumption (POA dataset), and one which did not (nPOA dataset). Both fixed and random 
effects models were studied. 
Results: According to the statistical tests, the psoriasis data did not violate the PO assumption 
but visual inspection indicated a partial violation of the PO assumption. Analyses of the 
psoriasis data showed that the PO fixed effects model had the lowest residual deviance 
(18.1 versus 20.9) and uncertainty (62% lower SE). In the POA dataset, the PO fixed effects 
model had the lowest residual deviance (54.8 versus 58.9 for the ML model) and uncertainty 
of treatment effects (49% lower standard error (SE)). In the nPOA dataset, the predictions of 
the PO model were biased, and the ML model had the lowest residual deviance (52.7 versus 
271.0 for the PO model).
Conclusions: Statistical selection of NMA models for ordered outcomes should be based 
on the satisfaction of the PO assumption and size of the deviance measures. If data satisfies 
the PO assumption, the PO model differentiated treatment effects better as a result of 
lower uncertainty. In terms of flexibility, the PO model can handle data from studies that 
use different cut-offs for response categories and the ML model can be applied to datasets 
violating the PO assumption.







Meta-analyses provide techniques that allow the estimation of relative effect sizes of 
treatments by combining results from numerous studies, which compare the same 
treatments in order to improve precision of estimated relative effects and gain insight in 
heterogeneity.[1, 2] Network Meta-Analysis (NMA) allows the comparison of relative treatment 
effects even when direct head-to-head evidence does not exist.[3] Traditionally, NMAs are 
used to inform clinicians and formulary committees on the relative efficacy and safety of 
different treatments and the significance of these effects. Nowadays NMAs are also applied 
to provide input into health economic evaluations for reimbursement purposes, such as the 
multiple technology appraisals, which are conducted by the National Institute for Health and 
Care Excellence (NICE).[4, 5]
Meta-analyses and NMAs are often based on binary outcomes (e.g. relapse/remission) or 
continuous outcomes (e.g. mean/median), where logistic or linear models are typically 
applied. Guidance exists for NMAs considering linear or binary outcomes[1, 2], and a checklist 
was published for reviewing evidence synthesis concerning any outcome type.[6] However, 
clinical studies often report patient outcomes on a categorical scale. This scale may be 
ordered; for example cancer patients may be reported as having “no response”, “partial 
response” or “complete response” to treatment. On the other hand, some studies present 
multinomial endpoints, which are not ordered; for example: “discontinuation due to 
treatment”, “discontinuation due to other reasons” and “relapse”. With such categorical data, 
different types of models may be applied in an NMA framework.
The NICE Decision Support Unit (DSU) has published a technical guidance for NMA, and 
suggested two models for analyzing categorical data: 1) multinomial logistic (competing risk) 
model and 2) multinomial probit model (ordered categorical).[7] Besides these modelling 
frameworks, a proportional odds (PO) model  has been applied for meta-analyses of ordered 
categorical data.[8] The PO model has different underlying statistical assumptions and 
properties compared to the multinomial logistic (ML) model, which have consequences on 
model fit, interpretability of relative treatment effects and amount of uncertainty in model 
parameters. Differences in the magnitude and uncertainty of effect sizes can have major 
formulary implications. For health economic evaluations, the uncertainty of economic 
model outcomes is strongly related to the uncertainty of the input parameters. Therefore, 
NMA results with higher uncertainty potentially influences model robustness.
The PO model has not been implemented for NMA, and no published literature exists 
evaluating the relative merits of the PO and ML model for NMA in terms of deviance, 
uncertainty and statistical properties. Such findings would be useful for researchers trying 
to determine which technique will perform best on a particular ordered categorical dataset.
The objective of this study is to qualitatively and quantitatively compare the PO model and 
the more flexible ML model for the NMA of ordered categorical data in a psoriasis dataset 
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and in two extreme hypothetical oncology datasets; one (almost) perfectly satisfying the PO 
assumption and one extremely violating the PO assumption. Both fixed and random effects 
models were studied. 
Methods 
Psoriasis data
The NMA models were fitted into the data from five clinical trials investigating the efficacy 
of etanercept 25mg, etanercept 50mg or efalizumab versus ‘supportive care’ (placebo) in 
psoriasis patients.[9–13] The evidence network diagram is presented in Figure 1. The outcome 
of interest was the improvement of symptoms measured with the Psoriasis Area and Severity 
Index (PASI). This continuous outcome was categorized into three response groups (i.e. R1 
= 0-50% improvement, R2 = 50-75% improvement and R3 = more than 75% improvement). 
Most studies reported on four categories of improvement, i.e. R1 = 0-50% improvement, R2 
= 50-75% improvement, R3a = 75-90% improvement and R3b = >90% improvement.[10–13] 
However, the category R3b included maximally 1 patient, so this group was merged with 
the category with R3a to form R3. The random effects model could not be evaluated in these 
data, because the number of patients in the best category R3 was too low. Data of these trials 
was also published in the NICE DSU. [7] 
The PO model assumes that the data fulfils the PO assumption. The PO assumption requires 
that the odds ratio (OR) of having a R1 is similar to the OR of having at most R2 within each 
trial.[14] Statistical testing showed that the PO assumption was not violated in any of the 
included psoriasis clinical trials. However, visual inspection suggested a violation of the PO 
assumption for the comparison of etanercept 50mg versus placebo in the study of Leonardi 
(2003).[11] The log OR of R1 (-2.81) and at most R2 (-3.26) seemed relatively large. 
Figure 1: Network of psoriasis trials included in the network meta-analysis. Every edge represents 
a treatment and the position of the capital letter between brackets in the alphabet corresponds 
with the number that is assigned to that treatment in the modelling exercise. A line connecting the 
treatments indicate a direct comparison and the number along that line represents the number of 
trials containing that direct comparison.







To further study model performance, two additional oncology datasets were constructed 
(Table 3). A different indication was chosen for the simulated data to highlight the applicability 
of these types of models in different diseases. In the first simulated oncology dataset, 
treatment effects fulfilled the PO assumption strictly in each study (POA dataset). In the 
second dataset, the PO assumption was purposefully violated for all treatment comparisons 
(further referred to as non-proportional odds assumption (nPOA) dataset). 
Each constructed dataset included the same network diagram including 20 studies, 5 
different treatments and 3 response categories (Figure 2). For purpose of interpretation we 
defined the three categories from best to worse as complete response (CR), partial response 
(PR) and no response (NR). These are frequently used ordinal response categories in clinical 
trials in for instance oncology and dermatology. In the nPOA dataset, the OR of CR is often 
the opposite direction of the OR of having at least a PR (i.e. any response) within the trials 
(Table 3).
Treatment effects were heterogeneous, to reflect data of clinical trials included in NMA 
conducted in daily research practice. Heterogeneity was simulated such that treatment 
effects in terms of the ORs in smaller studies deviate from the ORs in larger studies as a result 
of chance. 
Figure 2: Network of evidence. Numbers indicate the number of randomized trials available for a 
particular head-to-head comparison. Capitals A to E indicate the treatment arms.
Statistical analysis
Adherence or violation of the PO assumption for each randomized controlled trial was 
checked by comparing the OR for the first category with the OR for the first two categories 
and by statistical testing, based on a likelihood-ratio test. In this statistical test, the beta 
coefficients from the PO model (which assumes the same cumulative logit for each response 
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category) are compared to the beta coefficients from the non-proportional odds model 
(which assumes different cumulative logits).[15]
The NMAs were conducted within a Bayesian framework. As the data contain ordered 
categorical outcomes, the likelihood which relates the data to the parameters of the models, 
was specified as ),(~ iTiTkiTk nplmultinomiar . With iTkp  being the probability for 
response in category  in patients treated with treatment T in study i , iTkr  the number 
of patients within each outcome category  and iTn  the total number of patients with 
treatment T in study i . 
The multinomial logistic model
The first modelling approach was based on a competing risk NMA model, previously published 
in the NICE DSU[7] and by Ades et al.[16] For modelling ordered categorical outcomes, the fixed 
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The treatment labels are assigned such that in each study, one treatment, b , is designated 
as the base treatment (control arm). Base treatments have labels A , B  or C  in the psoriasis 
data, and base treatment D  was added in the simulated data. The non-base treatments z
are labelled as B , C , and D  in each study of the psoriasis data, and treatment E  was 
added in the simulations. The non-base treatments z  follow all the base treatments in the 
alphabet. Treatment A  is taken to be the reference treatment for all analyses, but note that 
b  is not necessarily treatment A . iTkY  is the odds for category  among all patients for 
treatment T in study i . (The odds are only estimated for category 1 and 2, because the odds 
for category 3 is inherent for ordered categorical outcomes.) ika is the log odds for category 
1 or 2 for base treatment  in study . ibzkb  is the relative effect for treatment z  versus 
b , and is estimated for response categories 1 and 2 separately. ibzkb  are identified by 
expressing them in terms of the reference treatment A : bkzkibzk dd −=b  with 01 =Ad .
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where ibzkd  is the trial-specific treatment effect of treatment z  relative to treatment 
b  contributing to the k th log odds. These trial-specific effects are drawn from a Normal 
distribution: ),( 2kibzkNormal sb . The between study variance 
2
ks  is assumed constant 
for all treatment comparisons, however, is specific for outcomes k  (i.e. R1 and R2 or PR and 
CR).
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Vague Normally distributed priors were put on all base treatment effects and relative 
treatment effects: )(0,1000~ 2Normalika  and )1000,0(~ 2Normalibzkb  respectively. A vague 






The PO NMA model was based on a previously published PO model for meta-analyses [8, 
18]. The current PO model is based on cumulative probabilities, and predicts the log odds 
of iTkQ , which is the probability of category R1 for 1=k  and the probability of at most 
category R2 for 2=k  (i.e. R1 + R2). In the current data with 3 response categories (i.e. R1, 
R2, R3), two probabilities Q  are thus estimated for each treatment T  in study i  and the 
probability of at most category R3 (i.e. R1 + R2 + R3) is set to 100%. The fixed effects PO model 
for NMA was specified as
0
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where  ika  are the log odds for category 2,1=k  for base treatment  in study . bzb  
is the relative effect for treatment z  versus , and was fixed for all response categories k
. By estimating a common bzb  for all response categories, the PO model assumed that the 
treatment responses have a PO pattern. Note that  ika  are estimated per response category 
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k , and that the PO assumption of this model applies only to the relative treatment effects 
bzb .
The random effects PO model for two-arm trials can be specified as
0
),(),(~
2,1     
 ),( if
D)C(,B,A, ),( if
                                     
































where ibzd  is the trial-specific treatment effect of z  relative to treatment . These trial-
specific effects are drawn from a Normal distribution: ),(~ 2sbd bzibz Normal . Again, the 
pooled log ORs, bzb , are identified by expressing them in terms of the reference treatment 
A . The heterogeneity 2s  is assumed constant for all treatment comparisons and response 
categories.
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Vague Normally distributed priors were set on base treatment effects, separately for  1=k  
and 2=k : ))I(,(0,1000~ 221 ii Normal aa  and ),)I((0,1000~ 122 ii Normal aa . For 1ia , 
the I  indicate that the prior for the probability of R1 ( 1=k ) cannot be higher than the 
probability of R1 + R2 ( 2=k ). For 2ia , the I  indicate that the prior for the probability of 
R1 + R2 (k=2) cannot be lower than the probability of R1 ( 1=k ). Vague Normally distributed 
priors were put on the relative treatment effects: )1000,0(~ 2Normalbzb  and a vague inverse 












Model parameters were estimated using a Markov Chain Monte Carlo (MCMC) method 
as implemented in the WinBUGS software package.[19] The WinBUGS sampler, using three 
chains, was run for 100,000 iterations, with the first 20,000 discarded as ‘burn-in’ to allow 
for convergence of the parameters. Posterior distributions are therefore based on the 
subsequent 80,000 samples. Convergence was confirmed by the Gelman-Rubin statistic and 
visual inspection of trace plots representing values of key model parameters (i.e. the baseline 
treatment effect, the relative treatment effects and the between study variance in the random 
effects model) during the MCMC simulations.
Model comparison
A measure recommended for comparing the fit of different model specifications in WinBUGS 
is the deviance information criterion (DIC).[7, 20] Besides this measure, models were also 
















for trial i  in treatment arm T . iTkr  is the number of patients per outcome category . 
iTkrˆ  is the model estimated number of patients per outcome category . A lower DIC or 
residual deviance indicates a better model fit.
The PO and ML models were also compared in terms of relative uncertainty. The relative 
uncertainty was calculated by summing the standard errors (SEs) of the log ORs for category 
one and two for all treatment comparisons per model and dataset. Subsequently, the relative 
difference of the sum of the SEs was calculated over the models per dataset. For the nPOA 
dataset the uncertainty was not calculated, as the PO model showed biased outcomes. 
Results
Psoriasis dataset
Figure 3 shows the log ORs and corresponding 95% confidence intervals for limited (R1=0-50% 
of the PASI) and moderate (R2=50-75% of the PASI) improvement, for each trial comparison. 
It also shows the corresponding 95% credible intervals for the direct and indirect OL and 
ML model predictions. It seems predicted log ORs of both models are in line with the data 
published in the clinical trials. As mentioned previously, visual inspection of the trial data 
indicated a violation of the PO assumption for the comparison of etanercept 50mg versus 
placebo in the study of Leonardi (2003).[11] However, the difference in the log OR of PO and ML 
models was limited (i.e.  <0.1) for both outcome categories (Figure 3). The highest difference 
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in PO and ML model predicted outcomes was found for the indirect comparison of etanercept 
25mg versus efalizumab; here, the difference in the log OR for limited response was 0.4.
The PO model did have the best model fit, as indicated by the residual deviance and the DIC 
(residual deviance 18.10 for the PO model versus 20.79 for the ML model) (Table 2). 
Finally, the PO model reduced the uncertainty by 62%. The PO model had the lowest 
uncertainty, as expressed in the 95% credible intervals, especially for the predictions for 
treatment comparisons for which limited (placebo versus etanercept 25mg) or no data (the 
indirect comparisons) was available. This is explained by the fact that the PO model estimated 
one relative treatment effect per comparison based on data from all categories (under the 
assumption of proportional odds), while the ML model estimated relative treatment effects 
per category. The category for moderate and high improvement included low numbers of 
patients (Table 1), and this likely resulted in a larger uncertainty of the log OR predicted by 
the ML model. 
In the psoriasis dataset only fixed effects models were estimated due to the low sample sizes 
and the low number of trials in this dataset.
Simulated data POA dataset
Figure 4 shows the log ORs for CR and for PR, and corresponding 95% confidence intervals, 
for each trial in the POA dataset. Also, model predicted log ORs and 95% credible interval 
estimates for the pairwise log ORs are shown for ML and PO model. The plot suggests 
strong consistency between the ML and PO model’s estimated effects in terms of log ORs 
for treatment comparisons for which head-to-head trial evidence was available. The point 
estimates of the log ORs were also in line for the indirect treatment comparisons (Figure 6).
Table 4 illustrates the residual deviance for all models when applied to both the POA dataset 
and nPOA dataset. The fixed and random effects PO models showed the lowest and therefore 
best residual deviance and DIC in the POA dataset. The PO model having the lowest residual 
deviance may be unexpected, because the model did have the lowest number of parameters 
contributing to model fit. As such one might expect that the fit would be worse. However, 
the large uncertainty of the parameter estimates of the ML model relative to the PO model 
show that the Gibbs sampler applied to the models resulted sometimes in more extreme 
parameter estimates for the ML model, which resulted in a corresponding higher residual 
deviance.
The PO model reduced the uncertainty with 49% compared to the ML model in this dataset. 
When comparing the uncertainty of the PO model with that of the ML model, it can be seen 
that the credible intervals of the PO predicted log ORs are substantially smaller for partial 
response. For the log ORs of complete response, the credible intervals seem quite similar 
to those of the ML model. This can be explained by the fact that the (fixed effect) PO model 
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Table  1:  The  number  of  patients  per  improvement  category  per  treatment  arm  for  each  included  psoriasis  trial.  428	  
No. Study Treatment 
Improvement Total  
(N) 0%  50-75%  > 75%  
1 Gottlieb 2003 A 49 5 1 55 
  
B 17 23 17 57 
2 Elewski 2007 A 175 12 6 193 
  
C 44 54 96 194 
3 Leonardi 2003 A 142 18 6 166 
  
C 43 40 81 164 
4 Lebwohl 2003 A 103 13 6 122 
  
D 112 68 52 232 
5 Gordon 2003 A 161 18 8 187 
    D 153 118 98 369 





Table  2:  Residual  deviance  and  DIC  for  both  models  fitted  in  the  psoriasis  data  431	  
	  
Residual	  Deviance	   DIC	  
Multinomial	  logistic	  model	   20.79	   127.55	  
Proportional	  odds	  model	   18.10	   121.89	  
Grey  cells:  lowest  deviance/DIC  
    Table  3:  Numbers  of  patients  in  (a)  constructed  POA  dataset  (b)  constructed  nPOA  dataset.  432	  
Study Tx	  arm #	  CR #	  PR #	  NR OR	  CR
OR	  any
response Study Tx	  arm #	  CR #	  PR #	  NR OR	  CR
OR	  any
response
1 A 32 97 25 1.85 1.83 1 A 45 80 30 1.19 0.48
B 19 94 40 B 40 100 16
2 A 70 133 48 1.59 1.53 2 A 60 134 47 1.40 0.48
B 50 138 68 B 46 169 25
3 A 53 100 30 1.05 1.03 3 A 40 53 19 1.71 0.63
B 50 99 30 B 28 73 13
4 A 69 137 89 1.49 1.50 4 A 69 137 89 1.49 0.50
B 51 131 118 B 51 196 53
5 A 13 26 11 1.34 1.32 5 A 54 84 69 1.50 0.50
B 10 25 13 B 38 122 40
6 A 30 40 14 1.67 1.67 6 A 46 92 40 1.51 0.49
B 20 40 20 B 33 121 22
7 A 35 63 29 1.47 1.53 7 A 20 35 20 2.15 0.68
B 25 59 38 B 11 50 15
8 A 47 135 34 1.52 1.49 8 A 47 135 34 1.51 0.48
B 34 138 48 B 34 167 18
9 A 57 107 55 1.20 1.19 9 A 57 107 55 1.20 0.40
C 50 108 63 C 50 145 26
10 A 37 50 23 1.74 1.74 10 A 20 45 27 1.03 0.42
C 25 51 35 C 20 60 14
11 A 39 78 41 1.08 1.10 11 A 20 28 13 1.40 0.68
C 36 76 43 C 15 34 9
12 A 111 151 68 1.20 1.18 12 A 111 151 68 1.20 0.39
C 99 156 78 C 100 205 31
13 B 57 124 90 0.60 0.60 13 B 57 124 90 0.60 0.20
D 84 126 63 D 84 164 25
14 B 31 85 46 0.64 0.63 14 B 30 85 46 0.60 0.20
D 43 85 32 D 44 104 12
15 B 33 50 31 0.76 0.77 15 B 25 40 25 0.74 0.26
D 39 48 25 D 30 50 8
16 B 72 109 83 0.80 0.80 16 B 72 109 83 0.80 0.26
E 83 107 70 E 83 148 28
17 B 25 65 34 0.97 0.95 17 B 12 53 24 0.67 0.34
E 25 64 32 E 17 63 10
18 B 19 45 41 0.51 0.51 18 B 18 36 31 0.95 0.26
E 31 46 25 E 19 56 11
19 B 43 127 55 0.80 0.80 19 B 43 127 55 0.80 0.27
E 51 126 46 E 51 154 18
20 B 51 111 95 0.80 0.79 20 B 51 111 95 0.80 0.26
E 60 114 81 E 60 160 34
POA  dataset nPOA  dataset
Tx=  treatment;  CR=  complete  response;  PR=  partial  response;  NR=  no  response;  OR=  odds  ratio. 	  433	  






includes two baseline parameters and one effect parameter per treatment comparison. 
The (fixed effect) ML model has two baseline parameters and two effect parameters. As a 
consequence the uncertainty is smaller in the PO model. Also, the PO model is a cumulative 
logit model, and thereby utilizes a higher sample size for the estimation of the log OR for 
partial response. 
As expected, the log ORs of the random effect models showed wider uncertainty margins 
than observed in the fixed effects model results in both PO and ML models. 
Simulated nPOA dataset
Figure 5 shows the log ORs for CR and for PR, and corresponding 95% confidence intervals, for 
each trial in the nPOA dataset. Also, model predicted log ORs and 95% credible interval for all 
pairwise log ORs in each model are shown. The PO model point estimates differ substantially 
from both the trial outcomes and the ML model estimates for treatment comparisons with 
head-to-head trial evidence available (Figure 5). The indirect treatment comparisons also 
showed substantial difference of the ML and PO model outcomes (Figure 7). This obviously 
is a consequence of its use on a dataset which violated the PO assumption. Hence, the 
reduction in uncertainty by the PO model compared to ML model was neglected for this 
analysis, because PO model outcomes were biased in the nPOA dataset.
Table 4 shows that the ML models have the lowest and therefore best residual deviance and 
DIC in the nPOA dataset. 
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No. Study Treatment 
Improvement Total  
(N) 0%  50-75%  > 75%  
1 Gottlieb 2003 A 49 5 1 55 
  
B 17 23 17 57 
2 Elewski 2007 A 175 12 6 193 
  
C 44 54 96 194 
3 Leonardi 2003 A 142 18 6 166 
  
C 43 40 81 164 
4 Lebwohl 2003 A 103 13 6 122 
  
D 112 68 52 232 
5 Gordon 2003 A 161 18 8 187 
    D 153 118 98 369 
A=	  ‘supportive	  care’;	  B=	  etanercept	  25mg;	  C=	  etanercept	  50mg;	  D=	  efalizumab.	  429	  
	  430	  
 ‘ portive care’; B= etanerc pt 25mg; C= etan rcept 50mg; D= efalizumab.




Table  2:  Residual  deviance  and  DIC  for  both  models  fitted  in  the  psoriasis  data  431	  
	  
Residual	  Deviance	   DIC	  
Multinomial	  logistic	  model	   20.79	   127.55	  
Proportional	  odds	  model	   18.10	   121.89	  
Grey  cells:  lowest  deviance/DIC  
    Table  3:  Numbers  of  patients  in  (a)  constructed  POA  dataset  (b)  constructed  nPOA  dataset.  432	  
Study Tx	  arm #	  CR #	  PR #	  NR OR	  CR
OR	  any
response Study Tx	  arm #	  CR #	  PR #	  NR OR	  CR
OR	  any
response
1 A 32 97 25 1.85 1.83 1 A 45 80 30 1.19 0.48
B 19 94 40 B 40 100 16
2 A 70 133 48 1.59 1.53 2 A 60 134 47 1.40 0.48
B 50 138 68 B 46 169 25
3 A 53 100 30 1.05 1.03 3 A 40 53 19 1.71 0.63
B 50 99 30 B 28 73 13
4 A 69 137 89 1.49 1.50 4 A 69 137 89 1.49 0.50
B 51 131 118 B 51 196 53
5 A 13 26 11 1.34 1.32 5 A 54 84 69 1.50 0.50
B 10 25 13 B 38 122 40
6 A 30 40 14 1.67 1.67 6 A 46 92 40 1.51 0.49
B 20 40 20 B 33 121 22
7 A 35 63 29 1.47 1.53 7 A 20 35 20 2.15 0.68
B 25 59 38 B 11 50 15
8 A 47 135 34 1.52 1.49 8 A 47 135 34 1.51 0.48
B 34 138 48 B 34 167 18
9 A 57 107 55 1.20 1.19 9 A 57 107 55 1.20 0.40
C 50 108 63 C 50 145 26
10 A 37 50 23 1.74 1.74 10 A 20 45 27 1.03 0.42
C 25 51 35 C 20 60 14
11 A 39 78 41 1.08 1.10 11 A 20 28 13 1.40 0.68
C 36 76 43 C 15 34 9
12 A 111 151 68 1.20 1.18 12 A 111 151 68 1.20 0.39
C 99 156 78 C 100 205 31
13 B 57 124 90 0.60 0.60 13 B 57 124 90 0.60 0.20
D 84 126 63 D 84 164 25
14 B 31 85 46 0.64 0.63 14 B 30 85 46 0.60 0.20
D 43 85 32 D 44 104 12
15 B 33 50 31 0.76 0.77 15 B 25 40 25 0.74 0.26
D 39 48 25 D 30 50 8
16 B 72 109 83 0.80 0.80 16 B 72 109 83 0.80 0.26
E 83 107 70 E 83 148 28
17 B 25 65 34 0.97 0.95 17 B 12 53 24 0.67 0.34
E 25 64 32 E 17 63 10
18 B 19 45 41 0.51 0.51 18 B 18 36 31 0.95 0.26
E 31 46 25 E 19 56 11
19 B 43 127 55 0.80 0.80 19 B 43 127 55 0.80 0.27
E 51 126 46 E 51 154 18
20 B 51 111 95 0.80 0.79 20 B 51 111 95 0.80 0.26
E 60 114 81 E 60 160 34
POA  dataset nPOA  dataset
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Tx=  treatment;  CR=  complete  response;  PR=  partial  response;  NR=  no  response;  OR=  odds  ratio. 	  433	  






Table  4:  Residual  deviance  and  DIC  for  all  four  models  across  both  datasets.  434	  
Residual	  Deviance	  
Proportional	  odds	  (POA)	  dataset	  
Non-­‐proportional	  odds	  (nPOA)	  
dataset	  
Fixed	  effect	   Random	  effects	   Fixed	  effect	   Random	  effects	  
Multinomial	  logistic	  model	   58.87	   66.50	   54.85	   63.40	  
Proportional	  odds	  model	   54.83	   55.84	   271.00	   275.80	  
     
DIC	  
Proportional	  odds	  (POA)	  dataset	  
Non-­‐proportional	  odds	  (nPOA)	  
dataset	  
Fixed	  effects	   Random	  effects	   Fixed	  effects	   Random	  effects	  
Multinomial	  logistic	  model	   522.69	   542.89	   505.47	   525.37	  
Proportional	  odds	  model	   514.54	   524.93	   717.48	   730.82	  
Grey  cells:  lowest  deviance/DIC  
      	  435	  
Table  5:  Qualitative  comparison  of  model  characteristics.  436	  
	   Proportional	  odds	  model	   Multinomial	  logistic	  model	  
Handling	  non-­‐proportional	  odds	  data	   -­‐	   +	  
Handling	  unordered	  categorical	  data	   -­‐	   +	  
Handling	  different	  cut-­‐offs	  of	  continuous	  
scale	  used	  for	  defining	  response	  categories	   +	   -­‐	  
Handling	  data	  with	  low	  statistical	  power*	   +	   -­‐	  
Interpretability	  model	  parameters	   +	   -­‐	  
*in	  terms	  of	  sample	  size	  and	  number	  of	  studies	  437	  
	  438	  
Figures  labels  439	  
	  440	  
Figure  1:  Network  of  psoriasis  trials  included  in  the  network  meta-­‐analysis.  Every  edge  represents  a  treatment  and  the  441	  
position  of  the  capital  letter  between  brackets  in  the  alphabet  corresponds  with  the  number  that  is  assigned  to  that  442	  
treatment  in  the  modelling  exercise.  A  line  connecting  the  treatments  indicate  a  direct  comparison  and  the  number  443	  
along  that  line  represents  the  number  of  trials  containing  that  direct  comparison.  444	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Table 5: Qualitative comparison of model characteristics.
*in terms of sample size and umber of studies







Different models exist for the analyses of ordered outcomes, however, literature describing 
and evaluating NMA models for ordered categorical outcomes is limited. This study 
compared the relative performance of the PO and ML model for NMA in datasets with ordinal 
categorical outcomes. The models were evaluated in clinical example (psoriasis) data and in 
two simulated oncology datasets of which one satisfied the PO criteria and the other violated 
it. These two extreme datasets were simulated to contrast (PO and ML) model performance.
The quantitative comparison of the PO and ML NMA models was based on model fit, bias and 
uncertainty of model predicted treatment effects. As expected, the residual deviance and 
DIC suggest that the most appropriate method for use in data satisfying the PO assumption 
is the PO model and for nPOA data the ML seems most appropriate. The lower number of 
parameters in the PO model, relative to the ML model, also resulted in less uncertainty of 
estimated treatment effects. 
In the real world psoriasis dataset, results are less unambiguous. Even though the statistical 
test showed that the psoriasis dataset fulfilled the PO criteria, visual inspection of the data 
suggested otherwise for one trial in the dataset. It is important to note that statistical tests 
assessing the PO assumption are not optimal, and researchers may use a subjective (eye-
balling) method to argue whether the dataset meets PO criteria.[14] Hence the PO model 
might be prone to biased point estimates of the treatment effects. The ML and PO models 
had similar DIC and Deviances, which were slightly in favor of the PO model. However, the 
combined uncertainty over the outcomes was reduced by 62% when comparing PO and 
ML model. This is an attractive property of the PO model for differentiating treatments in 
terms of formulary decisions, but also when performing sensitivity analysis in the setting 
of economic evaluations. The question now is which model (PO vs ML) makes statistically 
and clinically more sense in the psoriasis dataset, as the PO assumption might be partially 
violated. There is no generic answer to this question. However, as the ML and PO model 
have similar predictions for the trial in which the PO assumption seems partially violated, it 
seems appropriate to use the PO model. However, clinical validation of the PO assumption 
in ambiguous cases/trials is strongly recommended when facing such situation. Moreover, 
please note that the PO assumption is, however, not uncommonly satisfied in clinical 
practice.[14, 21, 22] 
The qualitative PO and ML model comparison resulted in three characteristics that differed 
among the models. First, the estimation of treatment effects per response category enable the 
ML model analyzing datasets violating the PO assumption and data reporting on unordered 
categorical outcomes. Second, the PO model can handle different cut-offs among studies of 
the outcome variable. For instance, if one psoriasis trial reported response categories based 
on PASI cut-offs of 30, 60 and 90, and another trial based on PASI cut-offs of 25, 50 and 75, 
the PO model can estimate relative treatment effects using data from both studies. [8] Third, 
the treatment effect of the ML model is not as easily interpreted, as indicated by formula 
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(3) and (4) in the methods section, and requires the transformation of model parameters to 
probabilities.
The models proposed can be extended in numerous ways. The PO model studied was based 
on cumulative probabilities. Alternative logits for ordinal categorical data are available, 
including the adjacent-category logits and continuation-ratio logits.[14, 23] Further, the probit 
link was presented in the NICE DSU.[7] This model requires a continuous variable underlying 
the categories. This was the case for the psoriasis dataset but not for the categorical CR, PR 
and NR dataset. Hence, the probit model was out of scope for purpose of present paper. 
Moreover, adjusting the probit model for categorical data only makes it very similar to our 
PO model. Heterogeneity was addressed by considering random effects models.[24] Clinical 
and methodological heterogeneity may also be addressed by meta-regression.[25] Although 
meta-regression models were out of scope for this study, regression parameters could have 
been readily included in each model. Further, although the studied datasets did not include 
trials with more than two arms, all investigated models can handle such a trial structure by 
implementing a multi-arm trial correction.[7]
The simulated POA and nPOA oncology datasets were constructed to contrast PO and 
ML model performance for known model characteristics. The simulated datasets were 
representative for daily research practice in terms of number of studies, size of studies and 
shape of evidence network.[2] However, endless variations are possible, with corresponding 
differences in performances of the two NMA modelling methods. Therefore, we aimed 
to review the NMA model properties quantitatively and qualitatively in a common setting 
instead of determining which has the best performance. The nPOA dataset seems a bit 
extreme, as the log OR for CR and any response had mostly different signs. The nPOA dataset 
was, however, constructed to illustrate model characteristics and performance. 
The present example considers three ordered response categories on PASI in psoriasis and 
on complete, partial on non-response in oncology to highlight the applicability of this type of 
meta-analyses across diseases. One could also apply it in for instance cardiovascular disease 
(ordered categories: ’no event’, ‘event’, ‘fatal event’) or different percentages of response in 
Parkinson’s disease. 
Conclusions
Statistical selection of NMA models for ordered outcomes should be based on the PO 
assumption and deviance measures. If data satisfies the PO assumption, the PO model 
differentiated treatment effects better as a result of lower uncertainty. In terms of flexibility, 
the PO model can handle data from studies that use different cut-offs for response categories 
and the ML model can be applied to datasets violating the PO assumption. 
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PO Proportional odds
POA Proportional odds assumption
PR Partial response
R1 0-50% improvement in PASI score
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R3 more than 75% improvement in PASI score
R3a 75-90% improvement in PASI score
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